Company: IONQ
Filing Date: 2025-11-10
Form Type: 424B7
Source: 0000950142-25-002919
Chunk: 4

Company: IonQ, Inc.
Filing Date: 2025-11-10
Form: 424B7
Chunk 4
---
 the Merger Agreement, on September 30, 2021, the Merger Sub was merged with and into
Legacy IonQ with Legacy IonQ continuing as the surviving corporation following the merger, becoming a wholly owned subsidiary of dMY,
and the separate corporate existence of the Merger Sub ceased (the “Business Combination”). Following the closing of the Business
Combination, dMY changed its name to IonQ, Inc., and Legacy IonQ changed its name to IonQ Quantum, Inc.

| S-1 |

Our principal executive offices are located
at 4505 Campus Drive, College Park, MD 20740, and our telephone number is (301) 298-7997. Our corporate website address is https://ionq.com.
Information contained on or accessible through our website is not a part of this prospectus supplement, and the inclusion of our website
address in this prospectus supplement is an inactive textual reference only.

| S-2 |

THE OFFERING

| Issuer                                          |     | IonQ, Inc.                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Common stock offered by the selling stockholder |     | Up to 2,108,993 shares of our common stock.                                                                                                                                                                                                                                                                                                                                                                                                       |
| Common stock outstanding prior to this offering |     | 354,279,591 shares of our common stock (as of October 29, 2025). The number                                                                                                                                                                                                                                                                                                                                                                       
 of outstanding shares of our common stock will not change as a result of this offering.                                                                                                                                                                                                                                                                                                                                                           |
| Use of proceeds                                 |     | The selling stockholder will receive all of the proceeds from the sale,                                                                                                                                                                                                                                                                                                                                                                           
 if any, of shares of our common stock in this offering. We will not receive any proceeds from the sale of shares of our common stock by                                                                                                                                                                                                                                                                                                           
 the selling stockholder. See the section titled “Use of Proceeds” for more information.                                                                                                                                                                                                                                                                                                                                                           |
| Risk factors                                    |     | Investing in our common stock involves significant risks. Before making an investment decision, please read the information contained in and incorporated by reference under the heading “Risk Factors” on page S-4 of this prospectus supplement and on page 4 of the accompanying prospectus, and under similar headings in other documents that are incorporated by reference into this prospectus supplement and the accompanying prospectus. |
| NYSE symbol                                     |     | Our common stock is listed on the NYSE under the symbol “IONQ”.                                                                                                                                                                                                                                                                                                                                                                                   |

| S-3 |